Comparison of Antiarrhythmic Activity and Safety of Russian-Made Drugs Containing Lappaconitine Hydrobromide

Aim. To compare the antiarrhythmic activity and safety of two Russian-made drugs, Laporitmin (PharmVILAR) and Allapinin (Pharmcenter VILAR) in premature ventricular contractions (PVCs) in patients without structural heart pathology.

Material and methods. The study included 100 subjects divided into 2 groups; the follow-up period was 3 weeks. The drug efficacy was assessed based on the results of ECG monitoring and Holter ECG monitoring (ECG-HM).

Results. A comparative analysis of the antiarrhythmic activity and safety of the drugs containing lappaconitine hydrobromide showed a comparably high clinical efficacy and good tolerability of the original drug Allapinin and the generic drug Laporitmin for PVCs. According to the results of ECG monitoring, the number of PVCs significantly decreased from 2 (2-6) to 0 (0-1) in patients of the main group (Laporitmin treatment group) and from 2 (2-7) to 0 (0-2) in patients of the control group (Allapinin treatment group) (p>0.05); according to the ECG-HM data, the number of PVCs significantly decreased by 88.2 Δ% in the main group and by 87.5 Δ% in the control group (p <0.01). There were no statistically significant differences in the primary effectiveness criterion between the main and control groups (F statistic = 1.41; p = 0.23).

Conclusion. The comparative analysis of the original drug Allapinin and the generic drug Laporitmin for PVCs in patients without structural heart pathology who had indications for antiarrhythmic therapy did not detect statistically significant differences in the primary criterion of effectiveness. Therapy with either drug showed a comparably high efficacy in reducing the number of PVCs by more than 75∆%, which was established as a criterion for primary effectiveness in the clinical trial protocol. Both drugs were well tolerated.

1. Ministry of Health of Russian Federation. Clinical recommendations. Ventricular arrhythmias. Ventricular tachycardia and sudden cardiac death. 2020. Av. at: https://congress-med.ru/assets/files/2020/2020rossijskie-rekomendaczii-po-vss-i-zhe.pdf.

2. Nguyen KT, Vittinghoff E, Dewland TA, Dukes JW, Soliman EZ, Stein PK et al. Ectopy on a Single 12‐Lead ECG, Incident Cardiac Myopathy, and Death in the Community. Journal of the American Heart Association. 2017;6(8):e006028. DOI: 10.1161/JAHA.117.006028

3. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS et al. Ventricular Ectopy as a Predictor of Heart Failure and Death. Journal of the American College of Cardiology. 2015;66(2):101–9. DOI: 10.1016/j.jacc.2015.04.062

4. Shimizu W. Arrhythmias originating from the right ventricular outflow tract: How to distinguish “malignant” from “benign”? Heart Rhythm. 2009;6(10):1507–11. DOI: 10.1016/j.hrthm.2009.06.017

5. Jamil HA, Mohammed SA, Gierula J, Paton MF, Lowry JE, Cubbon RM et al. Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. The American Journal of Cardiology. 2019;123(3):409–13. DOI: 10.1016/j.amjcard.2018.10.040

6. Sokolov S.F. Allapinin® and modern approaches to the treatment of cardiac arrhythmias. Russian Medical Journal. 2012;20(4):177–81.

7. Sokolov S.F. Allapinin: Review of the results of a clinical study. Doctor.Ru. 2010;3(54):40–1.

8. Lebedeva E.A., Yablonskaia Yu.A., Bulgakova S.V. Amiodarone-induced thyrotoxicosis: state of the art. Clinical and experimental thyroidology. 2017;13(2):31–8. DOI: 10.14341/ket2017231-38

9. Ioyleva E.E., Gavrilova N.A., Zinov’eva A.V., Kats M.V. Amiodaroneassociated optic neuropathy in the treatment of cardiovascular diseases. Russian Ophthalmological Journal. 2020;13(2):83–7. DOI: 10.21516/2072-0076-2020-13-2-83-87

10. Ivanov V.A., Gunov S.V. Ventricular extrasystole and the possibility of using antiarrhythmic drugs. Integrative trends in medicine and education. 2022;1:51–7.

11. Melnik M. Antirecurrent efficacy of lappaconitine hydrobromide in smoking patients. The Doctor. 2015;8:40–4.

12. Goldstein S, Brooks MM, Ledingham R, Kennedy HL, Epstein AE, Pawitan Y et al. Association Between Ease of Suppression of Ventricular Arrhythmia and Survival. Circulation. 1995;91(1):79–83. DOI: 10.1161/01.CIR.91.1.79

13. King GS, Goyal A, Grigorova Yu, Hashmi MF. Antiarrhythmic Medications. Treasure Island (FL): StatPearls Publishing; 2024. - 30p. Av. at: https://www.ncbi.nlm.nih.gov/books/NBK482322/.

14. Dolginina S.I., Duplyakov D.V. Allapinin’s place in cardiac arrhythmia therapy. Cardiology: news, opinions, education. 2016;2(9):25–9.

15. Sokolov S.F., Belyaeva M.M., Bakalov S.A., Golitsyn S.P. Lappaconitine hydrobromide and its prolonged form for ventricular extrasystole in patients without organic heart pathology: effectiveness and safety. Cardiology: news, opinions, education. 2018;2(17):29–37. DOI: 10.24411/2309-1908-2018-12004